Development PipelineSEA-TGT

an investigational sugar-engineered antibody directed to the immune checkpoint TIGIT

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

SGNTGT-001: Advanced solid tumors and lymphomas

  • Phase 1

  • Phase 2

  • Phase 3

Program Resources

High-level synopsis of SEA-TGT and ongoing clinical trials

Detailed information about SEA-TGT clinical trials